{"organizations": [], "uuid": "28fa817dc23339be31c25941c40b31b96b1baac6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-htg-molecular-diagnostics-inc-says/brief-htg-molecular-diagnostics-inc-says-on-march-30-2018-co-and-qiagen-manchester-limited-entered-second-amendment-of-first-statement-of-work-idUSFWN1RH0MW", "country": "US", "domain_rank": 408, "title": "BRIEF-HTG Molecular Diagnostics Inc Says On March 30, 2018, Co And Qiagen Manchester Limited Entered Second Amendment Of First Statement Of Work", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-05T00:27:00.000+03:00", "replies_count": 0, "uuid": "28fa817dc23339be31c25941c40b31b96b1baac6"}, "author": "", "url": "https://www.reuters.com/article/brief-htg-molecular-diagnostics-inc-says/brief-htg-molecular-diagnostics-inc-says-on-march-30-2018-co-and-qiagen-manchester-limited-entered-second-amendment-of-first-statement-of-work-idUSFWN1RH0MW", "ord_in_thread": 0, "title": "BRIEF-HTG Molecular Diagnostics Inc Says On March 30, 2018, Co And Qiagen Manchester Limited Entered Second Amendment Of First Statement Of Work", "locations": [], "entities": {"persons": [{"name": "marc", "sentiment": "negative"}], "locations": [{"name": "co", "sentiment": "none"}], "organizations": [{"name": "brief-htg molecular diagnostics inc", "sentiment": "negative"}, {"name": "qiagen manchester limited", "sentiment": "negative"}, {"name": "sec", "sentiment": "none"}, {"name": "first statement of work reuters", "sentiment": "none"}, {"name": "htg molecular diagnostics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "qiagen", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 5 (Reuters) - HTG Molecular Diagnostics Inc\n* HTG MOLECULAR DIAGNOSTICS INC - ON MARCH 30, 2018, CO AND QIAGEN MANCHESTER LIMITED ENTERED SECOND AMENDMENT OF FIRST STATEMENT OF WORK - SEC FILING\n* HTG MOLECULAR DIAGNOSTICS INC - QIAGEN HAS AGREED TO PAY COMPANY LOW, SINGLE-DIGIT MILLIONS OF DOLLARS IN DEVELOPMENT FEES FOR NEXT-PHASE ACTIVITIES\n* HTG- QIAGEN ALSO AGREED TO PAY CO MILESTONE UPTO AMOUNT IN LOW,SINGLE-DIGIT MLN OF DOLLARS ON ACHIEVEMENT OF SOME MILESTONES IN NEXT-PHASE ACTIVITIES\n* HTG MOLECULAR DIAGNOSTICS INC - THE NEXT-PHASE ACTIVITIES ARE EXPECTED TO BE COMPLETED IN Q2 OF 2018 Source text: ( bit.ly/2GZwjMW ) Further company coverage:\n ", "external_links": [], "published": "2018-04-05T00:27:00.000+03:00", "crawled": "2018-04-05T00:44:53.006+03:00", "highlightTitle": ""}